{
  "docId": "019de072-0fef-7225-bee8-4eafefc8a1ee",
  "docSlug": "7f14a86c142f5693f0e80c8dcf59a0d2",
  "documentTitle": "23andMe | Investor Presentation Deck | 63 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 63,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Includes a clinical trial flow diagram and endpoint table. Mentions strategic collaboration with GSK.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-0fef-7225-bee8-4eafefc8a1ee/41",
  "deckHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee",
  "deckJsonHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee.json",
  "deckAnchorHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.49,
        "x": 0.03,
        "y": 0.19
      },
      "kind": "diagram",
      "text": "Study design flow showing Arm A and Arm B progression",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a917829c-a696-4c42-855e-532bd2a6c1ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "ADA, anti-drug antibodies; AEs, adverse events; ORR, objective response rate; PK, pharmacokinetics; PK/PD, pharmacokinetics/pharmacodynamics; Q3W, every 3 weeks; RP2D, recommended Phase 2 dose",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0a5e39a-ac36-49a5-9659-d1bdef4d8003",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.03,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "https://www.clinicaltrials.gov/ct2/show/NCT04446351",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a9488f4-d322-4808-8369-e9151dbce720",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.46,
        "x": 0.51,
        "y": 0.39
      },
      "kind": "table",
      "text": "Study Endpoints table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f217b5f3-e97f-4669-9b9b-47107fa9fa50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Phase 1 Study Design for GSK6097608 (GSK'608): A High Affinity Monoclonal Antibody Against CD96",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39f64a66-9c33-4d89-90b9-f3e29e38d779",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Process flow",
      "slug": "process-flow",
      "agent": null,
      "layer": "slide",
      "matchId": "6866abdc-b85d-4292-b530-4ef4a8ac920e",
      "evidence": "The slide presents a study design flow showing Arm A and Arm B progression.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}